D&D Pharmatech Inc.
Research D&D Pharmatech Inc. (347850.KQ) on Bullrun: market cap KRW 1.75T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker347850.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 1.75T
- Financial periodQ2 2026
- RevenueKRW 662.06M
- Net income-KRW 8.27B
- Free cash flow-KRW 7.30B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 1.75T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 1.75T | n/a | n/a | n/a |
Dividend history
About D&D Pharmatech Inc.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is D&D Pharmatech Inc.'s market cap?
D&D Pharmatech Inc.'s market capitalization is KRW 1.75T.
What does D&D Pharmatech Inc. do?
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases.